TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27341466

Group type: EXPERIMENTAL
Intervention: Mandibular advancement splint (MAS) at 70% of maximum protrusion and 4 mm of vertical opening
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mandibular advancement splint (MAS) at 60% of maximum protrusion and 4 mm of vertical opening
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mandibular advancement splint (MAS) at 60% of maximum protrusion and 6 mm of vertical opening
Number of subjects: 72

Group type: COMPARATOR
Intervention: Mandibular advancement splint (MAS) at 70% of maximum protrusion and 6 mm of vertical opening
Number of subjects: 72
Study: 23778091

Group type: EXPERIMENTAL
Intervention: Wavefront-guided LASIK
Number of subjects: 36

Group type: COMPARATOR
Intervention: Wavefront-optimized LASIK
Number of subjects: 36
Study: 21787219

Group type: EXPERIMENTAL
Intervention: Aconitum napellus (30c potency)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Aconitum napellus (1M potency)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sulphur (200c and 1M potency)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Gelsemium (200c potency)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Pulsatilla (200c potency)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Gelsemium (1M potency)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Phosphorus (1M potency)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Sulphur (1M potency)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study: 19512981

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg daily
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 16460630

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 41

Group type: COMPARATOR
Intervention: Alcohol gel
Number of subjects: 41
Study: 15302456

Group type: EXPERIMENTAL
Intervention: Heliomolar Radiopaque (HR)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Tetric Ceram (TC)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Filtek Z250 (FZ)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Prodigy Condensable (PR)
Number of subjects: 4

Group type: COMPARATOR
Intervention: All materials tested
Number of subjects: 4
Study: 11404722

Group type: COMPARATOR
Intervention: OAC7 (Omeprazole 20 mg b.i.d., Amoxycillin 1 g, Clarithromycin 500 mg)
Number of subjects: 325

Group type: COMPARATOR
Intervention: OAM7 (Omeprazole 20 mg b.i.d., Amoxycillin 1 g, Metronidazole 500 mg)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: OTA7 (Omeprazole 20 mg b.i.d., Tetracycline 500 mg t.i.d., Amoxycillin 1 g b.i.d.)
Number of subjects: 325
Study: 10421667

Group type: COMPARATOR
Intervention: Interferon alfa-2b + placebo (monotherapy)
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b + ribavirin (combination therapy)
Number of subjects: 324
Study: 10155073

Group type: EXPERIMENTAL
Intervention: Voda guiding catheter
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amplatz guiding catheter
Number of subjects: 40
Study: 2750673

Group type: EXPERIMENTAL
Intervention: Warfarin (2.5 mg/day, adjusted to lower VIIc to 70% of standard and increase prothrombin time INR to 1.6)
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Placebo (same dose sequence as warfarin)
Number of subjects: 6000

Group type: EXPERIMENTAL
Intervention: Combined therapy (low-dose warfarin and low-dose aspirin 75 mg/day)
Number of subjects: 6000
Study: 835781

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) chemotherapy
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) chemotherapy to the point of toxicity
Number of subjects: 274

Group type: COMPARATOR
Intervention: Control group (no chemotherapy)
Number of subjects: 274
Study: 30526183

Group type: EXPERIMENTAL
Intervention: Cemented UKA
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cementless UKA
Number of subjects: 80
Study: 28339139

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 33224

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 33224
Study: 26280587

Group type: EXPERIMENTAL
Intervention: CHW-led, culturally specific, faith-based program to increase physical activity
Number of subjects: 0
Study: 23232805

Group type: EXPERIMENTAL
Intervention: Oral doxifluridine (800 mg/m2/day) in 3 divided doses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oral uracil/tegafur (UFT) (400 mg/m2/day) in 2 divided doses
Number of subjects: 100

Group type: COMPARATOR
Intervention: Doxifluridine group
Number of subjects: 100
Study: 21646066

Group type: EXPERIMENTAL
Intervention: Immediate mobilisation after Angio-Seal™ deployment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Delayed ambulation
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Implementation cohort (standard-care)
Number of subjects: 300
Study: 19671372

Group type: EXPERIMENTAL
Intervention: Topical mometasone 50 micrograms in each nostril once daily for 3 months
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo spray once daily for 3 months
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Topical mometasone
Number of subjects: 217

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study: 17057920

Group type: EXPERIMENTAL
Intervention: Amiodarone (600 mg three times a day, started 30-56 hours before surgery)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 93
Study: 15684785

Group type: EXPERIMENTAL
Intervention: Basic ultrasound training
Number of subjects: 28
Study: 11225504

Group type: EXPERIMENTAL
Intervention: Individual and group Cognitive Behavioral Therapy (CBT) and family anxiety management training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors, buspirone, and high‐potency benzodiazepines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychotherapy, pharmacotherapy, and both
Number of subjects: 0
Study: 9286523

Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RM-GIC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 40
Study: 9433396

Group type: EXPERIMENTAL
Intervention: 15 mg CGP 51901
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 30 mg CGP 51901
Number of subjects: 153

Group type: EXPERIMENTAL
Intervention: 60 mg CGP 51901
Number of subjects: 153

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study: 2667509

Group type: EXPERIMENTAL
Intervention: 2% MK-927
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 785442

Group type: EXPERIMENTAL
Intervention: Diflucortolone valerianate, 0.1%
Number of subjects: 52

Group type: COMPARATOR
Intervention: Flumethasone pivalate, 0.02%
Number of subjects: 52
Study: 31794072

Group type: EXPERIMENTAL
Intervention: SM-1 (a combination of diphenhydramine, zolpidem delayed release, and lorazepam delayed release)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: SM-1
Number of subjects: 0
Study: 28861651

Group type: EXPERIMENTAL
Intervention: Adapted Responsive Teaching (ART)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study: 25512454

Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 7576

Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 7576
Study: 23127290

Group type: EXPERIMENTAL
Intervention: Maintenance cognitive behavior therapy (M-CBT)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Assessment only (control)
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: M-CBT
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Residual symptoms of agoraphobia at the end of acute-phase treatment
Number of subjects: 379
Study: 22103994

Group type: EXPERIMENTAL
Intervention: Clinical algorithm for HIV presumptive diagnosis
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Clinical findings (oral thrush, hepatomegaly, lymphadenopathy, etc.)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Individual clinical signs
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: Clinical algorithm
Number of subjects: 542
Study: 18925985

Group type: EXPERIMENTAL
Intervention: 2 Hz rTMS treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham rTMS treatment
Number of subjects: 34
Study: 16968234

Group type: EXPERIMENTAL
Intervention: 60 mg iron orally twice a day for 3 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 15140310

Group type: EXPERIMENTAL
Intervention: Buffered commercial 1% xylocaine (with 1:200,000 adrenaline)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Unbuffered commercial 1% xylocaine (with 1:200,000 adrenaline)
Number of subjects: 85
Study: 11524329

Group type: EXPERIMENTAL
Intervention: small‐dose nalbuphine (0.2 microg/mL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: large‐dose nalbuphine (0.4 microg/mL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: atropine (1‐mg bolus and 0.5 mg/h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: control (no drug)
Number of subjects: 8
Study: 9263382

Group type: EXPERIMENTAL
Intervention: Drug A (antidepressant immediate-release product)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Drug B (antiepileptic controlled release product)
Number of subjects: 10
Study: 8348164

Group type: EXPERIMENTAL
Intervention: hCG therapy
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 61
Study: 3534852

Group type: EXPERIMENTAL
Intervention: Captopril 25 mg t.i.d.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study: 29888944

Group type: EXPERIMENTAL
Intervention: Thinking-aloud nominal group
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Interacting groups
Number of subjects: 156

Group type: COMPARATOR
Intervention: Quiet nominal group
Number of subjects: 156
Study: 26916033

Group type: EXPERIMENTAL
Intervention: Personalized Cognitive Counseling (PCC)
Number of subjects: 0
Study: 24275453

Group type: EXPERIMENTAL
Intervention: Inspiratory and expiratory muscle training (Threshold Inspiratory Muscle Trainer and Threshold Positive Expiratory Pressure) for 15 minutes each, twice a day, five days/week for eight weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham group with lowest loads for training
Number of subjects: 26
Study: 22773209

Group type: EXPERIMENTAL
Intervention: Bortezomib plus lenalidomide/thalidomide
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Bortezomib or lenalidomide/thalidomide
Number of subjects: 1200
Study: 20056391

Group type: EXPERIMENTAL
Intervention: Cognitive remediation therapy (CRT)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 85
Study: 17723312

Group type: EXPERIMENTAL
Intervention: Negative emotional priming
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Positive emotional priming
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neutral emotional priming
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pain-related pictures
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Somatoform pain disorder
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fibromyalgia
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pressure pain sensitivity
Number of subjects: 120
Study: 15709984

Group type: EXPERIMENTAL
Intervention: Pre-treatment with a proton pump inhibitor
Number of subjects: 773

Group type: COMPARATOR
Intervention: No pre-treatment with a proton pump inhibitor
Number of subjects: 773
Study: 12029512

Group type: EXPERIMENTAL
Intervention: Active ESWT (3 x 2000 pulses, energy flux density ED(+) 0.04 to 0.22 mJ/mm(2) under local anaesthesia)
Number of subjects: 272

Group type: COMPARATOR
Intervention: Placebo ESWT
Number of subjects: 272
Study: 10509497

Group type: EXPERIMENTAL
Intervention: 10 parts per million (ppm) inhaled nitric oxide
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control ventilation therapy without nitric oxide
Number of subjects: 204
Study: 7574002

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control Drama (Neutral)
Number of subjects: 22
Study: 1942779

Group type: EXPERIMENTAL
Intervention: 1 liter of 0.9% saline administered i.v. over one hour prior to amphotericin B
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1 liter of 5% dextrose in water administered i.v. over one hour prior to amphotericin B
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 6292981

Group type: EXPERIMENTAL
Intervention: d-amphetamine (20 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 30353619

Group type: EXPERIMENTAL
Intervention: linaclotide 0.5 mg
Number of subjects: 186

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 186
Study: 27586134

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Light intensity physical activity
Number of subjects: 247
Study: 26639039

Group type: EXPERIMENTAL
Intervention: HbA1c <6.5%
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: HbA1c 6.5% to 8.5%
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: HbA1c >8.5%
Number of subjects: 1145

Group type: EXPERIMENTAL
Intervention: Aspirin reaction units >550
Number of subjects: 1145
Study: 25127483

Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention (ILI)
Number of subjects: 5145

Group type: COMPARATOR
Intervention: Diabetes Support and Education (DSE)
Number of subjects: 5145
Study: 22219246

Group type: EXPERIMENTAL
Intervention: Piriformis-sparing approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard posterior approach
Number of subjects: 100
Study: 19683936

Group type: EXPERIMENTAL
Intervention: Adenosine (ADO) pretreatment (10‐min 100 microgkg(‐1)min(‐1) ADO) before application of the aortic cross‐clamp and antegrade 1 mmol l(‐1) adenosine high‐potassium ([K(+)]=20 mol l(‐1)) cold blood cardioplegia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (C) received antegrade cold (12 degrees C) high‐potassium ([K(+)]=20 mol l(‐1)) institute blood cardioplegia
Number of subjects: 30
Study: 17257464

Group type: EXPERIMENTAL
Intervention: Cannabidiol/THC buccal spray
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Cannabidiol
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Dronabinol
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: All cannabinoids pooled together
Number of subjects: 298

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298

Group type: COMPARATOR
Intervention: Cannabinoids vs Placebo
Number of subjects: 298
Study: 15023508

Group type: EXPERIMENTAL
Intervention: Integrated group therapy (IGT)
Number of subjects: 45

Group type: COMPARATOR
Intervention: No intervention (no IGT)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Substance use
Number of subjects: 45
Study: 11464374

Group type: EXPERIMENTAL
Intervention: No bed rest (Group N)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Bed rest (Group L)
Number of subjects: 38
Study: 9581366

Group type: EXPERIMENTAL
Intervention: Oral health awareness campaign (test group)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 98
Study: 8067402

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor (ANF) 50 micrograms over 3 min, then 50 ng.kg‐1.min‐1
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (vehicle)
Number of subjects: 6
Study: 2661155

Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (PGE1)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 4556543

Group type: EXPERIMENTAL
Intervention: Ergot alkaloid (2-Br-alpha-ergocryptine; ergocryptine; CB 154)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Stilboestrol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31371165

Group type: EXPERIMENTAL
Intervention: Symptom-based adjustment (SBA) with as-needed beclomethasone 80 μg and rescue short-acting β-agonist
Number of subjects: 206

Group type: COMPARATOR
Intervention: Provider-based guideline-directed adjustment (PBA) with maintenance beclomethasone 80 μg/d (6-11 years) or 160 μg/d (12-17 years)
Number of subjects: 206
Study: 29337780

Group type: EXPERIMENTAL
Intervention: Sodium picosulfate/magnesium citrate
Number of subjects: 341

Group type: COMPARATOR
Intervention: Ascorbic acid-enriched polyethylene glycol solution plus bisacodyl
Number of subjects: 341

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 341
Study: 28094466

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Intensive medical therapy alone for CHD with β-blockers
Number of subjects: 2244

Group type: EXPERIMENTAL
Intervention: Early revascularization for CHD with β-blockers
Number of subjects: 2244

Group type: COMPARATOR
Intervention: No β-blockers
Number of subjects: 2244
Study: 26154249

Group type: EXPERIMENTAL
Intervention: Directed self‐regulated learning (DSRL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Instructor-regulated learning (IRL)
Number of subjects: 40
Study: 23307544

Group type: EXPERIMENTAL
Intervention: Cognitive-enhancing drugs
Number of subjects: 2569
Study: 21590281

Group type: EXPERIMENTAL
Intervention: Rimonabant (CB(1) receptor antagonist) co-administered with ketamine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18499880

Group type: EXPERIMENTAL
Intervention: Metoclopramide oral solution 2 mg t.i.d.
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Metoclopramide tablets 5 mg t.i.d.
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 16458628

Group type: EXPERIMENTAL
Intervention: Laparoscopy‐assisted vaginal hysterectomy with bilateral oophorectomy (LAVHO)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Vaginal hysterectomy with bilateral oophorectomy without laparoscopic assistance (VHO)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: LAVHO
Number of subjects: 48

Group type: COMPARATOR
Intervention: VHO
Number of subjects: 48
Study: 15298758

Group type: EXPERIMENTAL
Intervention: Oat bran flakes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 15% coconut flakes
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: 25% coconut flakes
Number of subjects: 21

Group type: COMPARATOR
Intervention: Corn flakes (control)
Number of subjects: 21
Study: 11783378

Group type: EXPERIMENTAL
Intervention: PCIA
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: PCEA
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study: 9422301

Group type: EXPERIMENTAL
Intervention: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 5%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 25%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 75%
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Atracurium 0.2 mg/kg after succinylcholine 1 mg/kg recovery to 100%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (only atracurium)
Number of subjects: 50
Study: 8272018

Group type: EXPERIMENTAL
Intervention: 900 mg ASA
Number of subjects: 359

Group type: COMPARATOR
Intervention: 50 mg ASA
Number of subjects: 359
Study: 3305002

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 g per day) for 2 weeks in trial 1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 g per day) for 4 weeks in trial 2
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 0
Study: 30761976

Group type: EXPERIMENTAL
Intervention: Intervention group (CRTs receiving support from a facilitator, online resources, and fidelity reviews)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group (CRTs receiving no additional support)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 375

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 375
Study: 29254626

Group type: EXPERIMENTAL
Intervention: Hollowing lumbar stabilization exercise (HLSE)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Bracing lumbar stabilization exercise (BLSE)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 38
Study: 28590364

Group type: EXPERIMENTAL
Intervention: Bitopertin (10 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Mismatch negativity
Number of subjects: 29
Study: 26073148

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 41

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 41
Study: 23021323

Group type: EXPERIMENTAL
Intervention: Implant supported dental restoration in patients with chronic periodontal diseases (Group A)
Number of subjects: 60
Study: 21060260

Group type: EXPERIMENTAL
Intervention: Systane
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Optive
Number of subjects: 20
Study: 19025275

Group type: EXPERIMENTAL
Intervention: Experimental condition (questionnaire, plan to quit, form an implementation intention)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Active control condition (questionnaire plus instruction to plan to quit)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Passive control condition (questionnaire only)
Number of subjects: 350
Study: 16880425

Group type: EXPERIMENTAL
Intervention: Plant-based diet and stress management training
Number of subjects: 14
Study: 12974148

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol anesthesia
Number of subjects: 40
Study: 10788945

Group type: EXPERIMENTAL
Intervention: Moist environment dressings for venous leg ulcers
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional treatment for venous leg ulcers
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Moist environment dressings for pressure ulcers
Number of subjects: 70

Group type: COMPARATOR
Intervention: Traditional treatment for pressure ulcers
Number of subjects: 70
Study: 8829859

Group type: EXPERIMENTAL
Intervention: Ketorolac 0.75 mg.kg-1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketorolac 1.0 mg.kg-1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ketorolac 1.5 mg.kg-1
Number of subjects: 120

Group type: COMPARATOR
Intervention: Morphine 0.1 mg.kg-1
Number of subjects: 120